JP2015503588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503588A5 JP2015503588A5 JP2014551345A JP2014551345A JP2015503588A5 JP 2015503588 A5 JP2015503588 A5 JP 2015503588A5 JP 2014551345 A JP2014551345 A JP 2014551345A JP 2014551345 A JP2014551345 A JP 2014551345A JP 2015503588 A5 JP2015503588 A5 JP 2015503588A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- compound
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000029078 coronary artery disease Diseases 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 230000007211 cardiovascular event Effects 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 101150102415 Apob gene Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 230000007213 cerebrovascular event Effects 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584002P | 2012-01-06 | 2012-01-06 | |
| US61/584,002 | 2012-01-06 | ||
| PCT/US2013/020317 WO2013103842A1 (en) | 2012-01-06 | 2013-01-04 | Methods of reducing risk of cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018026939A Division JP2018104452A (ja) | 2012-01-06 | 2018-02-19 | 心血管疾患のリスクを低減する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503588A JP2015503588A (ja) | 2015-02-02 |
| JP2015503588A5 true JP2015503588A5 (enExample) | 2016-02-18 |
| JP6295205B2 JP6295205B2 (ja) | 2018-03-14 |
Family
ID=48745439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551345A Active JP6295205B2 (ja) | 2012-01-06 | 2013-01-04 | 心血管疾患のリスクを低減する方法 |
| JP2018026939A Pending JP2018104452A (ja) | 2012-01-06 | 2018-02-19 | 心血管疾患のリスクを低減する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018026939A Pending JP2018104452A (ja) | 2012-01-06 | 2018-02-19 | 心血管疾患のリスクを低減する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10028926B2 (enExample) |
| EP (2) | EP2800564B1 (enExample) |
| JP (2) | JP6295205B2 (enExample) |
| CN (2) | CN110025608A (enExample) |
| AU (1) | AU2013207423B2 (enExample) |
| CA (1) | CA2861643C (enExample) |
| HK (1) | HK1201452A1 (enExample) |
| MX (1) | MX367352B (enExample) |
| WO (1) | WO2013103842A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| US9440754B2 (en) | 2012-03-29 | 2016-09-13 | R.P. Scherer Technologies, Llc | Three circuit fill system for blow fill seal containers |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| SG10201912713YA (en) | 2014-11-14 | 2020-02-27 | Gemphire Therapeutics Inc | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| CN107530307A (zh) | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
| MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| EP3370713A4 (en) * | 2015-11-06 | 2019-10-23 | Gemphire Therapeutics Inc. | TREATMENT OF MIXED DYSLIPIDEMIA |
| CA3014919A1 (en) * | 2016-02-26 | 2017-08-31 | Gemphire Therapeutics Inc. | Treatment of patients with homozygous familial hypercholesterolemia on lipid-lowering therapy |
| MX2019009418A (es) * | 2017-02-08 | 2019-10-02 | Esperion Therapeutics Inc | Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
| CA3059073A1 (en) | 2017-04-18 | 2018-10-25 | Gemphire Therapeutics Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| US20190008779A1 (en) * | 2017-05-11 | 2019-01-10 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
| CN109666727B (zh) * | 2018-12-29 | 2020-11-06 | 中国药科大学 | 一种高活性抑制pcsk9表达的微小rna的用途 |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| EP4438114A3 (en) | 2019-06-21 | 2024-12-25 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
| CN113134086B (zh) * | 2020-01-20 | 2024-05-24 | 深圳市长卿医学研究院 | 一种降血脂的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US20020103252A1 (en) | 1997-12-12 | 2002-08-01 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| IL145712A0 (en) | 1999-04-01 | 2002-07-25 | Esperion Therapeutics Inc | Ether compounds, compositions, and uses thereof |
| US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| US6645170B2 (en) | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
| US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
| WO2007067817A1 (en) | 2005-12-07 | 2007-06-14 | Cv Therapeutics, Inc. | Abca1 elevating compounds |
| AU2007281212B8 (en) | 2006-08-03 | 2013-02-28 | Trustees Of Tufts College | Non-flushing niacin analogues, and methods of use thereof |
-
2013
- 2013-01-04 CN CN201910123564.7A patent/CN110025608A/zh active Pending
- 2013-01-04 CA CA2861643A patent/CA2861643C/en active Active
- 2013-01-04 EP EP13733913.1A patent/EP2800564B1/en active Active
- 2013-01-04 AU AU2013207423A patent/AU2013207423B2/en not_active Ceased
- 2013-01-04 HK HK15101958.1A patent/HK1201452A1/xx unknown
- 2013-01-04 CN CN201380004642.2A patent/CN104136023A/zh active Pending
- 2013-01-04 EP EP20166700.3A patent/EP3735967A1/en not_active Withdrawn
- 2013-01-04 MX MX2014008180A patent/MX367352B/es active IP Right Grant
- 2013-01-04 JP JP2014551345A patent/JP6295205B2/ja active Active
- 2013-01-04 WO PCT/US2013/020317 patent/WO2013103842A1/en not_active Ceased
- 2013-01-04 US US14/370,722 patent/US10028926B2/en not_active Expired - Fee Related
-
2018
- 2018-02-19 JP JP2018026939A patent/JP2018104452A/ja active Pending
- 2018-06-29 US US16/024,288 patent/US10709678B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6295205B2 (ja) | 心血管疾患のリスクを低減する方法 | |
| JP2017528427A5 (enExample) | ||
| RU2640115C2 (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| JP2016538248A5 (enExample) | ||
| JP2018536710A5 (enExample) | ||
| RU2018120726A (ru) | Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы | |
| KR20150125649A (ko) | 고용체 조성물들 및 심각한 통증에서의 이들의 용도 | |
| JP2015526458A5 (enExample) | ||
| RU2016129266A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| JP2004517148A (ja) | 心機能不全および心不全の治療における必須ｎ−３脂肪酸 | |
| JP2015503590A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| JP2018508551A5 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物 | |
| CN101374553B (zh) | 治疗患心血管病、脑血管病和其它血管病的患者的组合物和方法 | |
| CA2921985A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2021527129A5 (enExample) | ||
| AU2015237273B2 (en) | Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy | |
| JP2013536408A5 (enExample) | ||
| JP2024081650A (ja) | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 | |
| WO2013073884A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
| JP2023526418A5 (enExample) | ||
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| US20080146534A1 (en) | Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases |